NCT05007275View on ClinicalTrials.gov

A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers

PHASE1UnknownINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 10, 2021

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Covid19SARS-CoV-2 Infection
Interventions
BIOLOGICAL

1x10^9 vp AZD1222

A single dose of 1x 10\^9 vp AZD1222

BIOLOGICAL

5x10^9 vp AZD1222

A single dose of 5x 10\^9 vp AZD1222

BIOLOGICAL

1x10^10 vp AZD1222

A single dose of 1x10\^10 vp AZD1222

Trial Locations (1)

Unknown

Imperial College London, London

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

University of Oxford

OTHER

collaborator

AstraZeneca

INDUSTRY

lead

Imperial College London

OTHER

NCT05007275 - A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter